Hachi-mi-jio-gan extract (Harncare ; HE), a galenical produced from the traditional Chinese herbal mixture BaWei-Die-Huang-Wan, has been reported to improve lower urinary tract symptoms (LUTS) in patients. The present study was undertaken to clarify the pharmacological eŠects of HE on smooth muscle contraction and on pharmacologically relevant (muscarinic, 1,4-DHP and purinergic) receptors in the rat bladder. Additionally, the eŠects of repeated oral treatment with HE on the hepatic cytochrome P-450 (CYP) and on blood biochemical values in rats were examined. HE (10 mg/ml) inhibited signiˆcantly the acetylcholine-induced contraction of isolated rat bladder strips. The pD 2 value in the absence and presence of HE (10 mg/ml) was 5.14±0.16 and 3.99±0.17, respectively. HE (0.1 to 10 mg /ml) inhibited the speciˆc binding of .23 mg/ml. Based on IC 50 values, the binding activity of HE for purinergic receptors was shown to be signiˆcantly (about 7 times) greater than that for muscarinic and 1,4-DHP receptors. Repeated oral administration of HE (10, 30 and 100 mg/kg/day) for 4 weeks had little or no eŠect on the level and activity of hepatic CYP or on blood biochemical values in rats. In conclusion, the present study has shown that HE exerts signiˆcant binding activity for pharmacologically relevant receptors in the rat bladder and a relaxant eŠect on the acetylcholine-induced contraction of isolated muscle strips. HE seemed to exhibit little pharmacokinetic interaction with drugs.
INTRODUCTION
The number of patients with lower urinary tract symptoms (LUTS) such as urinary incontinence and urinary frequency is increasing, especially among the elderly. 1) Anticholinergic drugs are theˆrst choice in the treatment of LUTS. These agents inhibit the cholinergic contraction of bladder smooth muscle by blocking muscarinic receptors.
Hachi-mi-jio-gan (Ba-Wei-Di-Huang-Wan) is a traditional Chinese herbal preparation, composed of eight natural ingredients; Rehmanniae radix, Corni fructus, Dioscoreae rhizoma, Alismatis rhizoma, Hoelen, Moutan cortex, Cinnamomi cortex and Aconiti tuber. It has been used for the treatment of diabetes mellitus, hypertension, nephrotic syndromes, and glomerulonephritis since the late middle ages. 2, 3) In Japan, Hachi-mi-jio-gan extract (Harncare : HE) is currently used for the treatment of LUTS. 4) However, the eŠects of HE on bladder smooth muscle tone and autonomic receptors in the lower urinary tract have not been investigated.
Herbal products, including HE, are used frequently with other prescription medications. Thus, the potential for serious pharmacokinetic and pharmacodynamic interactions with drugs, particularly in elderly patients who are susceptible to the consequences of drug interactions, should be a concern. 5) There is little direct information about the pharmacokinetic eŠects of HE on hepatic drug-metabolizing (cyto- chrome p450: CYP) enzymes. Thus, the aim of this study was to clarify the eŠects of HE on the contraction of bladder smooth muscle, pharmacologically relevant receptors in the bladder, hepatic CYP and blood biochemical values in rats.
MATERIALS AND METHODS

Materials
HE was produced by Taiho Pharmaceutical Co. Ltd., Tokyo, Japan. The composition of the plant mixture used to obtain Harncare is given in Table 1 ％ B changing over 60 min to 0％ A and 100％ B was used. The ‰ow rate was controlled with the LC-10A at 1.0 ml/min. The eluate from the column was monitored, and the three-dimensional data were processed with a diode array detector (SPD-M10A; Shimadzu, Kyoto, Japan). The three-dimensional HPLC charts of the methanol solutions of HE are shown in Fig. 1 . Loganin and paeoni‰orin were detected as the major compounds of HE, while benzoylmesaconine, cinnamic acid, cinnamaldehyde and paeonol were also observed. Animals and Administration of HE Male Sprague-Dawley rats weighing 250 to 350 g were purchased from Japan SLC, Inc. (Hamamatsu, Japan). Rats were housed with a 12-hour light-dark cycle and fed laboratory food and water ad libitum. In the drug-metabolizing enzyme analysis and blood biochemical examination, rats received orally HE (10, 30 and 100 mg/kg/day) for 4 weeks. The control animals received vehicle alone. This study was done according to guidelines approved by the experimental animal ethics committee of the University of Shizuoka.
Acetylcholine-induced Contraction in Bladder Smooth Muscle Strips
Urinary bladder strips were isolated from the rats. The abdomen was opened, and the urinary bladder was dissected. Urinary bladder strips were cut longitudinally into two or three strips. The bladder muscle strips were suspended in a tissue bathˆlled with Krebs-Henseleit solution. The strips were maintained at 37°C in an atmosphere of 95％ O 2 and 5％ CO 2 . The response of the strips was measured isometrically under a resting tension of 1 g using a transducer (TB-612T, Nihon Kohden, Tokyo, Japan).
The concentration-response curves for acetylcholine were obtained by increasing the concentration in a stepwise manner after the response to the previous concentration had reached a plateau. The cumulative concentration-response curves were reproducible by applying acetylcholine at several times by appropriate intervals. The strips were then incubated with HE for 5 min and the concentration-response curves for acetylcholine were obtained in the presence of in- The radioligand-binding assays for muscarinic receptors, 1,4-DHP receptors and purinergic receptors were performed using
MeATP respectively, as previously described 6) . Rats were exsanguinated by taking the blood from the descending aorta under temporary anesthesia with diethyl ether and the aorta. The bladder and submaxillary gland were then dissected and the tissues were minced with scissors. The submaxillary gland was utilized to examine the binding activity of HE in exocrine muscarinic receptors. The diŠerence between the bladder and submaximally gland in the muscarinic binding activity of HE may be interesting issue because antimuscarinic agents for the treatment of LUTS cause frequently dry mouth as one of systemic side eŠects. In the case of binding assays for ice-cold 30 mM Na ＋ /HEPES buŠer (pH 7.5). The homogenates were then centrifuged at 40000×gravity for 20 min at 4°C. The resulting pellets wereˆnally resuspended in the ice-cold buŠer. For the [ 3 H]abMeATP binding assay, the bladder was homogenized in 10 volumes of ice-cold 50 mM Tris /HCl buŠer (pH 7.5) containing 1 mM EDTA, 2 mg/ml soybean trypsin inhibitor, and 10 mg/ml bacitracin. The homogenate was then centrifuged at 2000×gravity for 10 minutes at 4°C. The resulting pellet suspension was further centrifuged at 2000×gravity for 10 minutes at 4°C, and the supernatant was combined with the original supernatant. The supernatant was centrifuged at 48000×gravity for 20 minutes at 4°C and the suspension of the resulting pellet was used. In the displacement experiments, the rat tissue homogenates were incubated with [ The contractile responses of the bladder strips to acetylcholine (68.4 pM to 68.4 mM) were measured in the absence (control, •) and presence of HE (1 mg/ml, ▲; 10 mg/ml, ■ 
Preparation of Hepatic Microsomal and Cytosolic Fractions
After repeated oral administration of HE (10, 30, 100 mg/kg/day) in rats, the liver was dissected and stored at -80°C prior to analysis. The liver was homogenized in 50 mM Tris-HCl buŠer (pH 7.4) containing 0.25 M sucrose. The homogenate was centrifuged at 10000×gravity for 30 min at 4°C. The supernatant was further centrifuged at 105000×grav-ity for 60 min at 4°C. The supernatant was used as the cytosolic fraction for the assay of glutathione S-transferase, the activity of which was determined by the method of Habig et al. 7) using 1-chloro-2,4-dinitrobenzene as a substrate. The pellet was washed once with 50 mM Tris-HCl buŠer (pH 7.4) containing 0.25 M sucrose by centrifugation at 105000×gravity for 60 min at 4°C, and the concentration and activities of CYP were analyzed. Protein concentrations of microsomal and cytosolic fractions were determined using a BCA protein assay kit (Pierce, Rockford, IL).
Analysis of Drug Metabolizing Enzymes The CYP content was quantiˆed by the method of Omura et al. 8) The activities of glutathione S-transferase and various CYP enzymes were determined by HPLC as reported previously. 9) The subtypes of drug-metabolizing enzymes (corresponding CYPs) were methoxyresoruˆn O-demethylase (CYP1A2), ethoxyresorun O-deethylase (CYP1A1), pentoxyresoruˆn Odealkylase (CYP2B), p-nitrophenol hydroxylase (CYP2E1), testosterone 6b-hydroxylase (CYP3A) and (S)-warfarin 7-hydroxylase (CYP2C9).
Blood Biochemical Examination After repeated oral administration of HE (10, 30, 100 mg/kg/ day), the concentrations of total protein, albumin, triglyceride, phospholipids, total cholesterol, AST, ALT, ALP and g-GTP in plasma of rats were determined by Clinical Analyzer 7170 (HITACHI).
Data Analysis
For the analysis of acetylcholineinduced contractions of the isolated rat bladder, pD 2 values were calculated as described. 10 Figure 2 shows the concentration-response curves for acetylcholine-induced contractions of the isolated rat bladder strips in the absence and presence of HE (1, 10 mg/ml). HE at a concentration of 1 mg/ml had little eŠect on the acetylcyholine-induced contraction of the bladder, but at 10 mg/ml signiˆcantly inhibited the response. The pD 2 value for the control, and 1 and 10 mg/mL of HE was 5.14±0.16, 5.17± 0.18 and 3.99±0.17, respectively. The pD 2 value at 10 
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No. 8 mg/ml of HE was signiˆcantly ( p＜0.05) lower than the control value. In contrast, HE (1, 10 mg/ml) had little inhibitory eŠect on KCl (100 mM)-induced contraction in rat bladder muscles (data not shown).
EŠect on the Pharmacologically Relevant Receptors in the Bladder HE (0.1 to 10 mg/ml) inhibited the speciˆc binding of [ 3 H]NMS in the bladder and submaxillary gland of rats in a concentrationdependent manner (Fig. 3A) , with IC 50 values of 6.85±0.94 and 13.1±0.8 mg/ml, respectively. The IC 50 value was signiˆcantly (p＜0.05) lower in the bladder than in the submaxillary gland. Similarly, HE (0.1 to 10 mg/ml) inhibited the speciˆc binding of (Fig. 3B) 
EŠects of Repeated Oral Administration on Hepatic Drua-Metabolizing Enzymes and Blood Biochemical Values in Rats
Repeated oral administration of HE (10, 30 100 mg/kg/day) had little signiˆcant eŠect on body weight, CYP content and the activities of drug-metabolizing enzymes (glutathione S-transferase, ethoxyresoruˆn O-deethylase, methoxyresorun O-demethylase, pentoxyresoruˆn O-dealkylase, pnitrophenol hydroxylase, testosterone 6b-hydroxylase and (S)-warfarin 7-hydorylase) in the rat liver, compared with the corresponding control values ( Table  2) . Similarly, the repeated administration of HE had little eŠect on total protein, albumin, triglyceride, phospholipid, total cholesterol, GOT, GPT, ALP and g-GTP levels in rat blood ( Table 3) .
DISCUSSION
The usage of medicinal herbs has grown fast as complementary and alternative medicine, 12) but scientiˆc knowledge of the e‹cacy and safety of herbs is still lacking. Furthermore, the potential for interactions between herbs and drugs should be a concern because all herbs contain a large number of constituents.
HE is an extract of Hachi-Mi-Ji-O-Gan obtained using ethanol. HE is used clinically for the treatment of LUTS. 13, 14) Hachi-Mi-Ji-O-Gan has been shown to improve signiˆcantly maximum ‰ow rates and to reduce signiˆcantly scores of emptying, weak stream, total scores and quality of life scores according to the International Prostate Symptom Score (IPSS). 13) In a canine study using cystometry, Hachi-Mi-Ji-O-Gan inhibited the frequency of rhythmic bladder contractions and signiˆcantly increased both maximum vesical volume and eŠective vesical volume. 14) GOT: glutamic oxaloacetic transaminase, GPT: glutamic pyruvic transaminase, ALP: alkalinephosphatase, g-GTP: gglutamyl transpeptidase. Values are mean±S.E. for 5 to 7 rats.
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Vol. 129 (2009) There are many potential targets in the treatment of LUTS because its pathophysiology is multifactorial. 15) Pharmacologically relevant receptors such as muscarinic receptors, 1,4-DHP receptors and purinergic receptors in the bladder are considered as targets of therapeutic agents for LUTS. The present study has shown that HE inhibited the acetylcholine-induced contractions of rat bladder as well as the speciˆc binding of These results indicate that HE may bind to muscarinic receptors, 1,4-DHP receptors and purinergic receptors in the bladder. Thus, the inhibitory eŠects of HE on the acetylcholine-induced contractions of bladder muscle strips are mediated at least in part via antagonistic eŠects on muscarinic cholinoceptors. Since HE exerted little inhibitory eŠect on the KCl-induced contraction of isolated rat bladder strips, it is unlikely that HE inhibits directly the contractile elements of bladder smooth muscles. Furthermore, HE displayed approximately 2-fold lower binding a‹nity to the muscarinic receptors in the submaxillary gland than in the bladder (Fig. 3A) .
Notably, based on IC 50 values, the binding activity of HE for purinergic receptors in the rat bladder was shown to be signiˆcantly (about 7 times) greater than that for muscarinic and 1,4-DHP receptors. Thus, it is likely that HE exerts a signiˆcantly greater eŠect on the functions of purinergic receptors in the bladder. The binding activity of HE for purinergic receptors in the bladder is consistent with the recentˆnding that HE treatment reduced the expression of purinergic P2X 3 receptors and inhibited ATP-induced detrusor overactivity in the bladder. 16 ) Furthermore, the currentˆnding provides pharmacological evidence to support the notion that purinergic receptor-related mechanisms in the urothelium and smooth muscle may be altered in the bladder of patients with interstitial cystitis (IC). 17) ATP levels were signiˆcantly elevated in the urine of patients with IC and the stretch-activated release of ATP was augmented in the urothelium. 18) Rapp et al. 19) have suggested that purinergic (P2X) receptors may be a potential target for the treatment of disorders of the bladder. Thus, pharmacological agents that modify the functions of P2X receptors in the bladder are considered to counteract the symptoms mediated by abnormal purinergic signaling. 19) Taken together, HE might have some beneˆcial eŠects on patients with IC.
The potential for interactions between plant extracts and drugs should be a concern because the extracts contain a large number of constituents. 20 22) It is well established that St. John's wort (Hypericum perforatum) induces signiˆcantly hepatic CYP3A4 activity, thereby reducing the e‹cacy of therapeutic drugs such as cyclosporin, indinavir, and digoxin. 23) Repeated oral administration of HE had little signiˆcant in‰uence on the levels and activities of hepatic drug-metabolizing enzymes (CYP isoforms) or on blood biochemical parameters in rats. Therefore, it is unlikely that HE alters the disposition of coadministered drugs.
In conclusion, HE has been shown to exert signiˆcant binding activity for pharmacologically relevant receptors in the rat bladder with the inhibition of acetylcholine-induced contractions of smooth muscle. These eŠects of HE may be partly relevant in alleviating the urination dysfunction in patients with LUTS. Consequently, the present study may provide further pharmacological evidence of the e‹cacy and safety of HE in patients with LUTS.
